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Abstract
Background: Multi-drug resistant tuberculosis (MDR-TB) is a major public health concern since diagnosis is often delayed,
increasing the risk of spread to the community and health care workers. Treatment is prolonged, and the total cost of
treating a single case is high. Diagnosis has traditionally relied upon clinical suspicion, based on risk factors and culture with
sensitivity testing, a process that can take weeks or months. Rapid diagnostic molecular techniques have the potential to
shorten the time to commencing appropriate therapy, but have not been put to the test under field conditions.
Methodology/Principal Findings: This retrospective case-control study aimed to identify risk factors for MDR-TB, and
analyse the impact of testing for rifampicin resistance using RNA polymerase B (rpoB) mutations as a surrogate for MDR-TB.
Forty two MDR-TB cases and 84 fully sensitive TB controls were matched by date of diagnosis; and factors including
demographics, clinical presentation, microbiology findings, management and outcome were analysed using their medical
records. Conventionally recognised risk factors for MDR-TB were absent in almost half (43%) of the cases, and 15% of cases
were asymptomatic. A significant number of MDR-TB cases were identified in new entrants to the country. Using rpoB
mutation testing, the time to diagnosis of MDR-TB was dramatically shortened by a median of 6 weeks, allowing patients to
be commenced on appropriate therapy a median of 51days earlier than those diagnosed by conventional culture and
sensitivity testing.
Conclusions/Significance: MDR-TB is frequently an unexpected finding, may be asymptomatic, and is particularly prevalent
among TB infected new entrants to the country. Molecular resistance testing of all acid fast bacilli positive specimens has
the potential to rapidly identify MDR-TB patients and commence them on appropriate therapy significantly earlier than by
conventional methods.
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Introduction
There has been a resurgence of tuberculosis (TB) in the United
Kingdom (UK) since 1987, with an overall annual incidence in
England and Wales of 14 per 100, 000 in 2005 [1]. In London, the
incidence reached 46 per 100,000 in 2005, accounting for 45% of
all TB cases notified in the UK that year [1]. Multi-drug resistant
tuberculosis (MDR-TB) (by definition TB caused by Mycobacterium
tuberculosis resistant to at least rifampicin and isoniazid) requires
prolonged therapy with a combination of second line anti-
tuberculous drugs, many of which are less effective, more toxic
and more expensive than first line drugs [2]. Cases of suspected or
confirmed MDR-TB may require prolonged inpatient manage-
ment, extended periods of outpatient follow-up and present a
significant financial burden. In the UK the proportion of MDR-
TB in initial isolates has remained stable at 0.9–1.9% between
1994 and 2005 [1,3,4]. However, MDR-TB cases are not
uniformly distributed geographically, with higher than average
frequencies occurring in certain areas and population groups,
particularly in London and amongst asylum seekers [5].
A key element in the management of MDR-TB is the early
institution of an appropriate treatment regimen. Traditionally,
diagnosis has relied upon culture and sensitivity testing, a process
which can take weeks and sometimes months. Such a delay results
in increased patient morbidity and mortality, and may also lead to
the spread of MDR-TB both within the community and to
healthcare workers [6]. The development of rapid diagnostic
techniques for multi-drug resistance testing in tuberculosis cases is
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analysing for a mutation in the 69 base pair region (codon 507–
533) of the gene encoding the beta chain of RNA polymerase
(rpoB) arises in 95% of rifampicin resistant M. tuberculosis strains [7].
Since 83% of rifampicin resistant strains in the UK are also
isoniazid resistant, rifampicin resistance may be considered a
surrogate marker for MDR-TB [8,9]. Since 1997 all acid fast
bacilli (AFB) positive samples in our hospital have routinely been
sent to the Mycobacterium Reference Unit for testing for rpoB
mutations using the INNO-LiPA Rif.TB assay (Immunogenetics,
Zwijndrecht, Belgium) [9,10]. We undertook this study to examine
risk factors for MDR-TB in our patient population, to assess the
impact of the introduction of rpoB testing on clinical practice, and
to determine whether this test would hasten MDR-TB diagnosis in
patients where recognised risk factors did not apply, and thereby
translate into tangible benefits for both patients and their contacts.
Methods
Wherever appropriate we used the Strengthening the Reporting
of Observational Studies in Epidemiology (STROBE) recommen-
dations to improve the quality of our study [11,12].
Cases and controls
Northwick Park Hospital (NPH) is a university-affiliated district
general hospital in Northwest London, UK. Patients with
suspected TB come from three main sources; the local population,
the Health Control Units (HCUs) at London’s Heathrow and
Gatwick airports, and via tertiary referrals from other hospitals.
The HCUs screen new entrants (selected new immigrants, long-
stay visitors (.6 months), students from high risk countries and all
asylum seekers) with a chest x-ray (CXR) on arrival in the UK.
Those with a CXR suspicious of TB are generally referred to NPH
for assessment.
We retrospectively reviewed all cases of culture proven MDR-
TB diagnosed over a 22 year period between January 1982 and
December 2004 at NPH. Cases were identified by searching
microbiology laboratory records, inpatient diagnostic databases
and TB notifications for the local districts of Brent & Harrow. Two
patients found to be HIV positive were excluded from the study. A
control group of patients with fully sensitive TB (M. tuberculosis
sensitive to rifampicin, isoniazid , pyrazinamide , ethambutol and
streptomycin) was obtained by selecting the preceding and
subsequent fully sensitive cases for each MDR-TB patient. Where
the medical records of these control cases were unavailable we
used the next available appropriate case. Thus, for each MDR-TB
case we obtained two controls. By using this method we were able
to control for changes in presentation and management that might
have occurred over the time span of this study.
Analysis of case notes
For each case we assessed the patient’s demographics, clinical
presentation, microbiology findings, management and outcome.
The date of diagnosis of MDR-TB was defined as the date of
recognition, confirmed either by a positive probe for an rpoB
mutation or culture sensitivity results confirming at least rifampicin
and isoniazid resistance. Cure was defined as clinical with or
without confirmed microbiological resolution of the disease
without relapse of symptoms or positive culture. Cases with smear
positive pulmonary TB were confined in hospital until 3 successive
sputum specimens were found to be AFB smear negative. If these 3
specimens were subsequently found to be culture negative then no
further specimens were taken unless clinically indicated i.e. a
worsening chest X-ray, ongoing fevers, continued sputum
production. If any of the 3 specimens were culture positive then
samples were collected in clinic until two or more consecutive
samples were TB culture negative. In many cases symptoms
resolved on treatment and thus there was no possibility of
obtaining repeat specimens i.e. no longer producing sputum, CXR
cleared, resolved lymphadenopathy. Treatment duration was the
time on appropriate anti-tuberculous therapy, and the time of post
treatment follow-up was defined as the interval between cessation
of therapy and the last known contact with the patient. An adverse
drug reaction was defined as symptoms that resulted in the
suspension or cessation of one or more drugs. A commercial
radioimmunoassay was used to measure 25 hydroxy-vitamin D
levels (DiaSorin Ltd, Wokingham, Berks, UK).
Statistical Methods
Analysis of factors influencing whether patients had MDR-TB
or not were measured on a categorical scale and the effect of each
variable was examined using logistic regression. The individual
effect of each variable was first examined separately using
univariate analysis, and then the combined effect of the
explanatory variables on the occurrence of MDR-TB was
examined in a multivariate analysis. Only those factors that
showed evidence of a significant effect in the univariate analysis
were included in the multivariate analysis. A backwards selection
procedure was used to determine the final model, which involved
removing all non-significant variables one at a time until all
remaining variables were statistically significant.
The paired t-test was used to compare the time to diagnosis
using standard TB cultures with the time to diagnosis by rpoB
mutation testing for those patients who had values for both. The
outcomes for MDR-TB cases and controls were compared using
Fisher’s exact test for categorical outcomes. For continuous
outcomes the 2 groups were compared using either the unpaired
t-test for normally distributed factors, or the Mann-Whitney U test
for non-normally distributed outcomes.
Results
Between 1982 and 2004, of 2,914 TB patients managed at
NPH, 44 (1.5%) were found to have MDR-TB (Figure 1). Two
patients found to be HIV positive were excluded, leaving a total of
42 patients in our study. Data was collected for 84 fully sensitive
control cases. Controls were found to be representative of the
entire TB cohort in terms of geographical region of origin and
source of referral (data not shown).
The majority of MDR-TB cases (24/42, 57%) were referred
from the airports, whereas non MDR-TB cases (63/84, 75%) were
more often from the local resident population (p,0.001) (Table 1).
Neither age nor sex influenced the likelihood of having MDR-TB
(p=0.55 and 0.9 respectively) (Table 1). The non-MDR cases had
been in the UK significantly longer than MDR-TB cases (median
32 months and 0 months respectively, p=0.004), but this was no
longer significant after multivariate analysis (Table 1). Patients
from West Africa were overrepresented in the MDR-TB group;
73% had MDR-TB, constituting 19% of all MDR-TB cases in this
series (Table 1). Forty four percent of patients from South East
Asia (SEA) and 38% of those from the Indian subcontinent (ISC)
had MDR-TB and the lowest occurrence was in those of
European/Middle Eastern origin (24%). The most frequent ethnic
group among the controls were those from the ISC (42 cases), who
constituted 50% of fully-sensitive TB cases. Despite these
differences, the numbers in each group were small and country
of origin was not a significant risk factor in univariate analysis
(p=0.08) (Table 1).
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with 57% of MDR-TB patients having previously had TB
compared to only 6% of the controls (Table 1). A history of
previous contact with a known TB case was not predictive
(p=0.16) (Table 1). Of significance, in 43% of the MDR-TB cases
there were no identifiable risk factors at all for the presence of
MDR-TB. Furthermore, there were no clinical features that
distinguished MDR-TB from sensitive TB cases. Both groups were
equally likely to be asymptomatic at presentation (p=0.19), to
have a cough (p=0.24), fever (p=0.33), weight loss (p=1.0), or
lymphadenopathy (p=1.0) (data not shown). The proportion of
specimens containing acid fast bacilli (from sputum, gastric
washings, bronchoalveolar lavage or fine needle aspirate of a
lymph node) was comparable in the MDR-TB and control groups
(p=0.11–1.0) (Table 2).
Since 1997 all samples found to contain acid fast bacilli were
routinely tested for the rpoB mutation. Since then, 100% (14/14) of
those patients subsequently confirmed to have MDR-TB tested
positive for the rpoB mutation compared to none (0/12) of the
control patients (p,0.001) (Figure 1). One patient tested positive
for an rpoB mutation, but the organism was subsequently found to
be rifampicin mono-resistant on culture and was therefore
excluded from this study. The median time taken to obtain the
rpoB result was 9 days (range 7–43) in the MDR-TB group and 8
days (range 4–55) in the control group (Table 2). In comparison,
the time to obtain sensitivity results through standard mycobac-
terial culture and sensitivity testing was 51 days (range 33–115) in
the MDR-TB group, and 56 days (range 33–119) in the control
group. Thus rpoB testing provided a result 6–7 weeks earlier in
both groups (42 days and 48 days respectively) compared to
conventional culture and sensitivity testing (p,0.001). Of the 28
MDR-TB cases that did not have an rpoB test for any reason, 17
(61%) were positive for AFB on microscopy, and therefore could
potentially have been diagnosed and correctly treated earlier if the
rpoB test was used.
Other investigations were unhelpful in distinguishing MDR
from sensitive TB cases. The proportion of patients with a positive
tuberculin skin test (TST) was comparable between the 2 groups
for Mantoux (p=1.0) and Heaf (p=1.0) tests (data not shown),
and full blood count, urea and electrolytes and liver function tests
were also comparable. The MDR-TB patients had significantly
lower CRP values (MDR-TB median 11 mg/L, control group
median 32 mg/L, p=0.03), significantly higher lymphocyte
counts (MDR-TB mean 1.86109/L, control group mean
1.56109/L, p=0.04), and significantly more MDR-TB patients
had normal vitamin D levels (MDR-TB 54%, control group 12%,
p=0.007) (data not shown), although none of these factors could
be used to distinguish MDR-TB from a fully sensitive case.
The length of inpatient hospital stay was significantly longer in
the MDR-TB group, with a median of 32 days for MDR-TB
patients and 9 days for controls (p,0.001) (data not shown). As
expected, the duration of treatment was much longer in the MDR-
TB group with a median total duration of treatment of 18 months
(inter-quartile range (IQR) 13–24) in the MDR-TB group,
compared to 6 months (IQR 6–9) in the control group
(p,0.001) (Table 3). The MDR-TB patients suffered significantly
more adverse effects than those in the control group (47% of
MDR-TB patients, 21% of controls, p=0.003) (data not shown).
There was also an extended period of follow-up post treatment for
MDR cases compared to controls, with a median of 11 months
(IQR 1–24) in the MDR-TB group and 3 months (IQR 1–9) in the
control group (p=0.05) (Table 3). The outcomes differed
Figure 1. Flow chart illustrating the 22 year case-control patients selected for the study.
doi:10.1371/journal.pone.0003173.g001
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among those for whom outcome data was available, all the control
group and 86% of MDR-TB cases were cured. There were no
known deaths or treatment failures in the control group. For the
22 sputum positive MDR-TB patients the time between treatment
start and culture negativity was a median of 99 days, mean of 163
days. Only one of the control group had a repeat sputum cultured
as an outpatient, and this was found to be culture negative. In the
MDR-TB group the treatment failed in one case (2%) and three
patients died (7%). Outcome data was not available in 25% of
controls and 31% of MDR-TB cases due to patients being lost to
follow-up, transferred to another hospital or returning to their
country for origin (Table 3). Surgical intervention was required for
6 (14%) of the MDR-TB cases and 3 (4%) of the control group
(p=0.06) (Table 3).
Median treatment times and outcomes were comparable for
MDR-TB patients regardless of whether the diagnosis was made
by rpoB mutation or standard culture (p=0.35 and 0.9
respectively) (Table 4). A significant proportion of those MDR-
TB cases diagnosed by culture never received the correct
treatment (36% of culture diagnosed, 0% of rpoB diagnosed cases,
p=0.02) (Table 4). The reasons for this include patient death
before treatment was initiated, moving away before treatment was
started or not receiving the correct treatment for their sensitivities.
Most of the cases where the patients did not receive the correct
treatment for their sensitivities occurred early on in the case series.
Furthermore, those diagnosed by the presence of an rpoB mutation
were followed up for less time (median 7 months vs. 13 months),
although this difference was not significant in our case series
(p=0.32) (Table 4). Five of the 6 MDR-TB patients requiring
surgery were diagnosed by culture and sensitivity rather than by
rpoB test. This raises the possibility that delay in diagnosis resulted
in disease progression and the need for surgical intervention,
although the numbers were too small to be significant (p=0.65)
(Table 4). None of the MDR-TB patients diagnosed by rpoB probe
died, whereas 11% (3/28) of those MDR-TB cases diagnosed by
culture died (Table 4), although again numbers were too small to
test for significance.
Discussion
MDR-TB poses major management, public health and
diagnostic problems, and is often not considered until culture
and first line sensitivity tests become available, which may be 8
weeks or more after presentation. Indeed, in our series 43% of the
MDR-TB cases had no identifiable risk factors and were thus
unexpected. MDR-TB patients are often treated with convention-
al quadruple therapy in the first instance, with the risk of
Table 1. Comparison of risk factors amongst MDR-TB cases and controls.
Variable Group MDR-TB N (%)
Controls
N( % )
Odds Ratio
(95% CI)
P-value
univariate
P-value
multivariate
Age * NA NA NA 0.93 (0.74, 1.17) 0.55 NS
Sex Female 21 (34%) 41 (66%) 1
Male 21 (33%) 43 (67%) 0.95 (0.45, 2.00) 0.9 NS
Geographical regions of origin SEA 4 (44%) 5 (56%) 1
ISC 16 (38%) 42 (62%) 0.48 (0.11, 2.00)
West Africa 8 (73%) 3 (27%) 3.33 (0.51, 21.6)
Africa - other 9 (31%) 20 (69%) 0.56 (0.122, 2.6)
Europe/Middle East 4 (24%) 13 (76%) 0.38 (0.07 ,2.17) 0.08 NS
Unknown 1 1
Referral source Airport 24 (57%) 18 (43%) 1
Local 13 (17%) 63 (83%) 0.15 (0.06, 0.36)
Tertiary 4 (57%) 3 (43%) 1.00 (0.20, 5.04) ,0.001 0.003
Unknown 1 0
Time in UK 0–1 months 25 (58%) 18 (42%) 1
2–12 months 2 (22%) 7 (78%) 0.21 (0.04, 1.11)
13–60 months 5 (18%) 23 (81%) 0.17 (0.05, 0.54)
.60 months 8 (26%) 23 (74%) 0.25 (0.09, 0.69) 0.004 NS
Unknown 2 13
TB contact No 38 (36%) 69 (64%) 1
Yes 3 (18%) 14 (82%) 0.39 (0.11, 1.44) 0.16 NS
Unknown 1 1
Previous TB diagnosis No 15 (16%) 79 (84%) 1
Yes 24 (83%) 5 (17%) 23.7 (7.9, 71.4) ,0.001 ,0.001
Unknown 3 0
*Odds ratio given for a 10 year increase in age.
NA=Not applicable.
NS=Not significant.
SEA=Southeast Asia.
ISC=Indian subcontinent (India, Pakistan and Sri Lanka).
doi:10.1371/journal.pone.0003173.t001
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ethambutol whilst awaiting sensitivities. Advances in molecular
diagnostic techniques have the potential to significantly hasten the
diagnosis and institution of adequate therapy. Our retrospective
case-control study of all non-HIV-related cases of MDR-TB
diagnosed at our hospital over a 22 year period has shown, for the
first time, the significant impact that rapid molecular testing for
rifampicin resistance can make on the diagnosis and management
of MDR-TB in clinical practice.
The introduction of routine rpoB gene testing for all AFB
positive samples improved the time to diagnosis of MDR-TB by 6–
7 weeks compared to relying on culture and sensitivity testing.
Furthermore, a ‘negative’ rpoB test provided reassurance that the
organism was likely to be fully sensitive significantly earlier than
culture testing. As a result, MDR-TB patients diagnosed by rpoB
probe were commenced on appropriate MDR-TB treatment
regimens at least 7 weeks earlier than those for whom standard
culture and sensitivity testing was relied upon. This could be
critical in preventing disease progression, further drug resistance
and spread to other individuals.
The onlyother factorthatwasconsistently predictive ofMDR-TB
in our series was a previous history of TB, which was present in 57%
of cases. This confirms the findings of others [13–15] and applied
regardless of whether the patient received their treatment in the UK
or abroad. Surveillance data on MDR-TB prevalence throughout
the world remains sparse [16,17], but our results suggest that the
region (or country) of origin cannot be used to rule out MDR-TB. In
our series MDR-TB cases were more likely to have been referred
from the HCUs at airports than from the local community. HCU
referral is at the discretion of the immigration officer and is based
Table 2. Comparison of methods of diagnosis in MDR-TB cases and controls.
Variable Group MDR-TB N (%) Controls N (%) P-value
Sputum AFB Negative 9 (29%) 12 (38%) 0.6
Positive 22 (71%) 20 (62%)
GW AFB Negative 12 (55%) 13 (57%) 1
Positive 10 (45%) 10 (43%)
BAL AFB Negative 5 (45%) 14 (78%) 0.11
Positive 6 (55%) 4 (22%)
FNA AFB Negative 5 (100%) 16 (73%) 0.56
Positive 0 (0%) 6 (27%)
Asymptomatic No 33 (85%) 78 (93%) 0.19
Yes 6 (15%) 6 (7%)
RpoB mutation No 0 (0%) 12 (100%) ,0.001
Yes 14 (100%) 0 (0%)
Time to rpoB diagnosis NA 9 (8, 26)* 8 (6, 10)* 0.11
Time to culture sensitivity diagnosis NA 51 (42, 71)* 56 (46, 79)* 0.1
*Median (inter-quartile range (IQR)).
AFB=acid fast bacilli, GW=gastric washing, BAL=bronchoalveolar lavage.
FNA=fine needle aspiration of a lymph node/TB mass.
NA=Not applicable.
doi:10.1371/journal.pone.0003173.t002
Table 3. Comparison of outcomes for MDR-TB cases and controls.
Variable Group MDR-TB N (%) Controls N (%) P-value
Surgical intervention No 35 (86%) 79 (96%) 0.06
Yes 6 (14%) 3 (4%)
Treatment duration (months)* NA 18 (13, 24) 6 (6, 9) ,0.001
Follow-up post treatment (months)* NA 11 (1, 24) 3 (1, 9) 0.05
Outcome Cure 25 (60%) 63 (75%) 0.03
Failed/relapsed 1 (2%) 0 (0%)
Died 3 (7%) 0(0%)
Lost to follow-up 4 (10%) 4 (5%)
Follow-up elsewhere 4 (10%) 12 (14%)
Return to C of O 5 (12%) 5 (6%)
*Median (interquartile (IQR) range).
C of O=country of origin.
NA=not applicable.
doi:10.1371/journal.pone.0003173.t003
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the intended length of stay (usually .6 months). UK studies indicate
that approximately 60% of new entrants with active TB are not
identified until they later present to hospital [18,19]. This is likely to
include cases of MDR-TB entering the community, with the
potential for local spread beforethe symptoms develop,the diagnosis
is made and treatment is instituted. Indeed, 15% of MDR-TB
patients in our study were asymptomatic on presentation.
The financial implications of treating MDR-TB are substantial,
with estimates in the region of £60,000 (,$120,000) per case
when assessed in 2000 [20,21], although £100,000 (,$200,000)
per case may be a more realistic current figure. Since 1997 we
have sent 321 samples from AFB positive specimens for rpoB
testing. Of these, 14 (1 in 23) indicated MDR cases, and one case
was rifampicin resistant only. Each test costs £120 (,$240),
making a total expenditure of £38, 520 (,$77,000). Thus each
MDR case cost £2, 750 (,$5,500) to diagnose an average of 7
weeks earlier than by conventional culture and sensitivity testing.
This suggests a potential financial gain from making an early
diagnosis, particularly if new secondary contact cases are
prevented by earlier treatment of the index case. However, a full
cost-benefit analysis would be required to confirm this. Impor-
tantly, a recent WHO Expert Group report concluded that there is
sufficient evidence to justify the use of line probe assays for the
detection of MDR-TB in the developing world, where the majority
of MDR-TB cases reside [22]. The technology is advancing
rapidly and costs are coming down, with current estimates in the
region of USD17-35 per test depending on the test, thus an
affordable molecular MDR-TB test for poorer countries is a
definite possibility in the near future.
The number of donors subjected to rpoB testing in this study are
relatively small, and thus it is difficult to draw firm conclusions
about the treatment outcomes. Indeed a larger multicentre
analysis would be needed to provide this information. Fewer
MDR-TB patients diagnosed by rpoB required costly surgery, and
there were no deaths in the MDR-TB group diagnosed by rpoB
compared to 11% of those diagnosed by culture. This certainly
supports measures directed at early diagnosis and treatment,
although the numbers are too small to determine significance.
Delayed diagnosis is just one reason why there might have been
deaths among the culture diagnosed MDR-TB group only, but
there are a number of other plausible explanations.
The rpoB test was 100% sensitive and 92% specific for MDR-
TB diagnosis in our case series. A study from the Mycobacterium
Reference Laboratory in the UK has examined the laboratory
impact of the rpoB probe and reported a sensitivity and specificity
of .95% for the diagnosis of rifampicin resistance in 1,997 clinical
specimens [9]. Rifampicin resistance in the presence of isoniazid
sensitivity was found in 17.5% of rpoB mutant strains [9]. This
justifies our practice of continuing isoniazid therapy until full
culture and sensitivity results are available. Barnard et al. similarly
found that the rpoB test had a sensitivity of 99% and specificity of
100% for the diagnosis of smear-positive MDR-TB cases in a
routine diagnostic laboratory in South Africa, and also that it
performed well for smear-negative, culture-positive cases [23].
In summary our findings highlight important considerations in
the diagnosis and management of MDR-TB. Previous recognised
risk factors were often absent on presentation, but referral from a
port of entry into the country posed a distinct risk for MDR-TB,
highlighting the need for early screening of these cases. Rapid
Table 4. Comparison of MDR-TB cases diagnosed by rpoB mutation versus culture alone.
Variable RpoB diagnosed MDR-TB Culture diagnosed MDR-TB P-value
Number of patients 14 28
Median (IQR) in-patient days 51 (16, 81) 23 (9, 78) 0.56
Diagnosis and Treatment
Median (IQR) time to rpoB diagnosis (days) 9 (8, 26) NA
Median (IQR) time to culture diagnosis (days) 50 (38, 71) 52 (44, 76) 0.32
Median (IQR) time to starting correct treatment (days) 8 (1, 18) 59 (25, 95) 0.008
Cases (%) where MDR-TB treatment was not started for any reason 0 (0%) 10 (36%) 0.02
Cases (%) where correct treatment never started 0 (0%) 5 (18%) 0.15
Cases (%) died before correct treatment could be instituted 0 (0%) 3 (11%) 0.54
Cases (%) followed up elsewhere before MDR diagnosis 0 (0%) 2 (7%) 0.55
Cases (%) that underwent surgery 1/14 (7%) 5/28 (18%) 0.65
Median (IQR) length of treatment (months) 19 (18, 24), (n=10) 18 (13, 24), (n=23) 0.35
Median (IQR) length of follow-up (months) 7 (0, 17), (n=11) 13 (1, 40), (n=16) 0.32
Cases (%) that experienced any AE of drug treatment 7/14 (50%) 12/26 (46%) 1.00
Outcome
Cure 10 (71%) 15 (54%) 0.9
Failure/relapse 0 (0%) 1 (4%)
Lost to follow-up 1 (7%) 3 (11%)
Transferred to another institution 1 (7%) 3 (11%)
Death 0 (0%) 3 (11%)
Return to Country of Origin 2 (14%) 3 (11%)
IQR=interquartile range.
AE=adverse event.
doi:10.1371/journal.pone.0003173.t004
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diagnosis, commencement of appropriate treatment and to
improve outcome. Routine introduction of rapid molecular testing
for all AFB positive cases has the potential to have a major public
health impact on the treatment and prevention of spread of MDR-
TB.
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